SCHEMBL1263199

SCHEMBL1263199

CC(C)(C)OC(=O)N1CCc2c(nc(-c3ccc[nH]3)nc2C(F)(F)F)C1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.47
TNKS2 Q9H2K2 1/20 0.47
PARP2 Q9UGN5 1/20 0.47
RAF1 P04049 1/20 0.43
BRAF P15056 1/20 0.43
MTOR P42345 2/20 0.41
P2RX7 Q99572 1/20 0.40
F12 P00748 1/20 0.39
PDE10A Q9Y233 1/20 0.39
MAPT P10636 2/20 0.38
ESR2 Q92731 1/20 0.38
DPP4 P27487 6/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPK1 P28482 1/20 0.37
NR1H2 P55055 1/20 0.37
C5AR1 P21730 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1261353 0.84 MTOR (0.49) PARP1TNKS2PARP2RAF1BRAF
SCHEMBL1261938 0.83 PDE10A (0.51) PARP1TNKS2PARP2RAF1BRAF
SCHEMBL1262006 0.83 DPP4 (0.53) PARP1TNKS2PARP2RAF1BRAF
SCHEMBL1262953 0.81 MTOR (0.50) PARP1TNKS2PARP2RAF1BRAF
SCHEMBL1261187 0.81 DPP4 (0.53) PARP1TNKS2PARP2RAF1BRAF
SCHEMBL4391067 0.80 MTOR (0.49) PARP1TNKS2PARP2RAF1BRAF
SCHEMBL1262024 0.80 RAF1 (0.46) PARP1TNKS2PARP2RAF1BRAF
SCHEMBL1261149 0.80 GBA1 (0.51) PARP1TNKS2PARP2RAF1BRAF
SCHEMBL1260976 0.79 MTOR (0.46) PARP1TNKS2PARP2RAF1BRAF
SCHEMBL1262544 0.79 GPR119 (0.45) PARP1TNKS2PARP2RAF1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879848-B2 good inhibition activity versus Dipeptidyl Peptidase-IV (DPP-IV); Diabetes mellitus, obesity; 3-[2S-amino-4-oxo-4-(3-trifluoromethyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-butyl]-oxazolidin-2-one; compounds having an optionally substituted lactam ring structure LG LIFE SCIENCES, LTD. (KR) 2011-02-01 US disclosed
US-20080188471-A1 Dipeptidyl Peptidase-IV Inhibiting Compounds, Method Of Preparing The Same, And Pharmaceutical Compositions Containing The Same As An Active Agent LG LIFE SCIENCES, LTD. (KR) 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188471-A1 Dipeptidyl Peptidase-IV Inhibiting Compounds, Method Of Preparing The Same, And Pharmaceutical Compositions Containing The Same As An Active Agent DPP4, DPP7, DPP8 PARP1 4062/4885TNKS2 3591/4885PARP2 4433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.